tbuckley/cabot-search huggingface dataset:
Effects of Phorbol Esters on Normal and Tumorous Mouse Mammary Epithelial Cells Embedded in Collagen Gels&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: R C Guzman, R C Osborn, J E Richards, S Nandi
Journal: JNCI Journal of the National Cancer Institute (1983)

The effects of phorbol esters on mammary epithelial cells from BALB/cfC3H/Crgl "midpregnant mice" (i.e., mice at the midterm of pregnancy) and from mammary adenocarcinomas (also from BALB/cfC3H/Crgl mice) grown in a collagen gel matrix were studied. 12-O-Tetradecanoylphorbol 13-acetate (TPA), when added to the media, caused an increased proliferation of both normal and cancerous mammary epithelial cells in a dose-dependent manner. The degree of enhancement of proliferation by TPA ranged from no increase in cell number at 3% swine serum (SW) concentration to two to three times the number of cells in the control cultures when 10 or 25% SW was used. Optimal growth was obtained with a TPA concentration of 0.1 or 1.0 microgram/ml. Increasing the SW concentration (3, 5, 10, or 25%) enhanced the proliferative effect of TPA. Cholera toxin (0.01 microgram/ml) enhanced the proliferative effect of TPA on normal cells but had a variable effect on tumor cells. The addition of TPA also resulted in a morphologic change in the epithelial colonies from midpregnant mice and from mammary tumors and caused them to assume a fibroblastic appearance. The addition of 4 alpha-phorbol or 4 alpha-phorbol 12,13-didecanoate to mammary epithelial cultures had no proliferative or morphologic effect. The results demonstrate that TPA has a growth-promoting effect on normal and cancerous mouse mammary epithelial cells.
원저 : 우리나라 B형 및 C형 바이러스성 간견병증 환자에서의 간세포암 발생률의 비교에 대한 전향적 연구
Authors: 이효석, 이준행, 최문석, 김정룡 ( Hyo Suk lee), Jun Haeng Lee, Moon Suk Choi, Chung Yong kim
Journal: Clinical and Molecular Hepatology (1996)
Clinical Courses of 133 Mgus and 73 Smoldering Multiple Myeloma Registered in Kansai Myeloma Forum
Authors: Kensuke Ohta, Satoru Kosugi, Masayuki Kobayashi, Junya Kuroda, Hirokazu Tanaka, Shin-ichi Fuchida, Hirohiko Shibayama, Nobuhiko Uoshima, Eiji Nakatani, Yuzuru Kanakura
Journal: Annals of Oncology (2014)
Karnofsky memorial lecture. Ode to methotrexate.
Authors: J R Bertino
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.1.5 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8418242 Karnofsky memorial lecture. Ode to methotrexate. J R BertinoxJ R BertinoSearch for articles by this author Show More Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. https://doi.org/10.1200/JCO.1993.11.1.5 First Page PDF © 1993 by American Society of Clinical Oncology
Abstract 12791: Soluble Lectin-Like Oxidized LDL Receptor-1 (LOX-1) and LOX Index Are Useful Biomarkers for Vulnerable Plaques
Authors: Tomofumi Misaka, Hiroyuki Kunii, Kazuhiko Nakazato, Hiroyuki Mizukami, Nobuo Sakamoto, Koichi Sugimoto, Shu-ichi Saitoh, Tatsuya Sawamura, Kagehiro Uchida, Toshiyuki Ishibashi, Yasuchika Takeishi
Journal: Circulation (2010)

Backgrounds:  Soluble LOX-1 (sLOX-1) is elevated in peripheral blood of patients with acute coronary syndrome (ACS). LOX index is a novel predictive biochemical marker for coronary heart disease, determined as multiplying sLOX-1 by LOX-1 ligands containing apolipoprotein B (LAB) [LOX index = sLOX-1 × LAB]. However, sLOX-1 in coronary circulation has not been examined. Furthermore, significance of LOX index in ACS has not been defined.   Aim:  We investigated the values of sLOX-1 and LOX index in systemic circulation and coronary circulation.   Methods:  This study enrolled 67 patients with ischemic heart disease (IHD) including 27 patients with ACS and 40 patients with effort angina pectoris (EAP) who underwent percutaneous coronary intervention (PCI). We measured the levels of sLOX-1 and LAB in blood samples from aorta (Ao) and coronary sinus (CS) at the same time just prior to PCI by newly established ELISA systems.   Results:  Both Ao and CS sLOX-1 were significantly higher in ACS than in EAP as well as Ao and CS LOX index were significantly higher in ACS than in EAP, but not LAB. The values of sLOX-1 and LOX index of CS were significantly higher than those of Ao in both ACS and EAP. The difference of sLOX-1 and LOX index between CS and Ao (CS-Ao) were greater in ACS than in EAP. These findings suggested that elevated sLOX-1 and LOX index were derived from coronary circulation. ROC curve showed that both Ao and CS sLOX-1 and LOX index can significantly discriminate ACS from EAP among patients with IHD, with no significant difference in AUC between Ao and CS values. Correlation between sLOX-1 and CK-MB, Troponin-I or CRP in ACS was not significant, probably because sLOX-1 of ACS appeared to be increased earlier after onset compared to other markers.   Conclusions:  The present study showed that systemic increased sLOX-1 originated from coronary circulation, suggesting that sLOX-1 was a specific biomarker of vulnerable plaque in ACS as well as LOX index.
Lamination of the Outer Plexiform Layer in Optic Atrophy Caused by Dominant WFS1 Mutations
Authors: Anna Majander, Maria Bitner-Glindzicz, Choi M. Chan, Holly J. Duncan, Patrick F. Chinnery, Malavika Subash, Pearse A. Keane, Andrew R. Webster, Anthony T. Moore, Michel Michaelides, Patrick Yu-Wai-Man
Journal: Ophthalmology (2016)
Cost-effectiveness projections of FOLFOX vs. IFL in first-line therapy of metastatic colorectal cancer in the context of the U.S. health care system
Authors: B. E. Hillner, D. Schrag, D. J. Sargent, C. S. Fuchs, R. M. Goldberg
Journal: Journal of Clinical Oncology (2005)

3531 Background: A randomized comparison has shown FOLFOX to be superior to the previous U.S. standard of care, IFL for 1st-line therapy (Rx) of metastatic colon cancer. The tradeoffs between costs and survival for these two regimens have not been explored. Methods: A post-hoc incremental cost-effectiveness (ICE) projection using simulated cohorts of patients starting FOLFOX or IFL was tracked for major clinical events, toxicities and survival for 5 years using the perspective of Medicare as a 3rd party payer. Recurrence and survival risks were based on clinical trial data. Resource use was projected using observed dose intensity, duration of and delays in Rx, and grade >2 toxicities. Use of 2nd-line Rxs was estimated based on patterns observed for trial patients as well as contemporary estimates. Results: Initial Rx with FOLFOX v IFL had an average incremental cost of $29,523, a survival benefit of 4.4 months and an ICE of $80,410 per life yr (LY). The table compares component costs. Using the 95% confidence interval for the time to progression observed in N9741, the ICE associated with FOLFOX ranged from $121,220 to $59,250 per LY. In the clinical trial, dose delays and skipped doses were frequent. If progression-free pts were treated without delay for the first yr or lifetime, the ICE for FOLFOX increased to $117,910 and $222,200 per LY, respectively. Otherwise, the ICE changed minimally across a range of plausible parameters. The ICE increased to $84,780 per LY when the model used a revised IFL schedule with lower early toxicity and similar rates of Rx with 2nd-line regimens. Conclusions: Compared to IFL, FOLFOX provides substantial benefit at substantial increase in cost. The ICE falls in the upper range of commonly accepted oncology interventions in the U.S. This cost analysis supports FOLFOX as a standard for future comparisons to regimens that incorporate biologic agents. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi-Synthelabo Pfizer, sanofi-aventis, Sanofi- Synthelabo Pfizer, sanofi-aventis, Sanofi-Synthelabo Pfizer, Sanofi-Synthelabo
Morphological and Biophysical Properties of the Mason-Pfizer Monkey Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Manning, JaRue S., Hackett, Adeline J.
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Morphological and Biophysical Properties of the Mason-Pfizer Monkey Virus Get access JaRue S. Manning, JaRue S. Manning Cell Culture Laboratory, Naval Biomedical Research Laboratory, School of Public Health, University of California, Berkeley, California 94625 Search for other works by this author on: Oxford Academic PubMed Google Scholar Adeline J. Hackett Adeline J. Hackett Cell Culture Laboratory, Naval Biomedical Research Laboratory, School of Public Health, University of California, Berkeley, California 94625 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 2, February 1972, Pages 417–422, https://doi.org/10.1093/jnci/48.2.417 Published: 01 February 1972 Article history Received: 10 August 1971 Accepted: 14 October 1971 Published: 01 February 1972
Abstract 5330: Methioninase-loaded erythrocytes: a promising drug for L-methionine restriction therapy in cancer
Authors: Fabien Gay, Julie Bes, Vanessa Bourgeaux, Yann Godfrin
Journal: Cancer Research (2015)

Abstract Several studies reported a complete dependence of different tumor cells on L-methionine (Met), an essential amino acid, for maintaining their high proliferation rate while normal cells keep their ability to grow on Met-deprived medium (Cavuoto and Fenech, 2012). Met restriction appearing as an important strategy for cancer treatment, different therapeutic approaches using either Met restricted regimens or Met-catabolizing enzymes were investigated. Phase I and II clinical trials associating dietary Met restriction with chemotherapy were conducted with cancer patients (Thivat et al., 2009; Durando et al, 2010). A 40% reduction of plasmatic methionine was achieved with a 1-day Met-free diet per month. Interesting long-duration of disease stabilization was observed in some patients. However this diet is extremely difficult to maintain. In order to obtain longer Met depletion in plasma, enzyme therapy using Methionine gamma-lyase (MGL), a pyridoxal-dependent enzyme that specifically degrades Met into alpha-ketobutyrate, ammonia and thiols, was explored. MGL enzyme isolated from Pseudomonas putida was selected as preferred candidate for the development of therapy. However, preclinical studies conducted in primates showed a very short half-life of the active form of MGL enzyme (2h) due to a rapid in vivo dissociation of the pyridoxal (PLP) cofactor (Yang et al., 2004). To overcome this problem of PLP-dissociation, we encapsulated the active MGL into erythrocytes, natural pool of PLP in the body and evaluated PK-PD parameters of product over a 5-day period in a mouse model. Once entrapped into erythrocytes, the MGL enzyme maintained more than 30% of its specific activity after 5 days in circulation. A 60-70% Met depletion was achieved 15 min post-injection and then depletion was stabilized at 40% over the 5 day-period of the study. In comparison, administration of the free MGL at similar doses led to a rapid loss of the active form in several hours. Met was totally deprived 15 min post-injection but plasmatic Met level returned to baseline by 24h. Increasing two-fold the concentration of free methioninase did not improved the in vivo Met depletion. In conclusion, we report that methioninase-loaded-erythrocytes can lower Met concentration in mouse plasma for at least 5 days and may be an innovative strategy to kill tumors by met-starvation. Citation Format: Fabien Gay, Julie Bes, Vanessa Bourgeaux, Yann Godfrin. Methioninase-loaded erythrocytes: a promising drug for L-methionine restriction therapy in cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5330. doi:10.1158/1538-7445.AM2015-5330
Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease
Authors: Gwilym Webb, Yung-Yi Chen, Ka-Kit Li, Desley Neil, Ye Htun Oo, Alex Richter, Venetia Bigley, Matthew Collin, David H. Adams, Gideon M. Hirschfield
Journal: Journal of Hepatology (2016)

Background & AimsAutoimmune hepatitis (AIH), an immune-mediated liver disease, originates as a consequence of interacting genetic and environmental risk factors. Treatment remains non-specific and prone to side effects. Deficiencies in regulatory T cell (Treg) function are hypothesized to contribute to the pathogenesis of AIH.MethodsWe describe an adult patient who presented with AIH in the context of monocytopenia. The patient was characterized by GATA2 gene sequencing, flow cytometry of peripheral blood for leucocyte subsets, ELISA for serum Flt-3 ligand, and immunohistochemistry of liver biopsy tissue.ResultsSequencing confirmed a GATA2 mutation. Peripheral Treg were absent in the context of a preserved total T cell count. Immunostaining for the Treg transcription factor FOXP3 was reduced in liver tissue as compared to a control AIH specimen. There were marked deficiencies in multiple antigen-presenting cell subsets and Flt-3 ligand was elevated. These findings are consistent with previous reports of GATA2 dysfunction.ConclusionsThe association of a GATA2 mutation with AIH is previously unrecognized. GATA2 encodes a hematopoietic cell transcription factor, and mutations may manifest as monocytopenia, dendritic and B cell deficiencies, myelodysplasia, and immunodeficiency. Tregs may be depleted as in this case. Our findings provide support for the role of Tregs in AIH, complement reports of other deficiencies in T cell regulation causing AIH-like syndromes, and support the rationale of attempting to modulate the Treg axis for the therapeutic benefit of AIH patients.
Intensive therapy in elderly patients with acute myeloid leukemia.
Authors: P A Cassileth
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.5.937 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2332774 Intensive therapy in elderly patients with acute myeloid leukemia. P A CassilethxP A CassilethSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.5.937 PDF "Intensive therapy in elderly patients with acute myeloid leukemia.." Journal of Clinical Oncology, 8(5), pp. 937–938© 1990 by American Society of Clinical Oncology
Comparative Morphologic Study of the Virus-Induced Solid Tumors of Syrian Hamsters&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Leonard D. Berman
Journal: JNCI Journal of the National Cancer Institute (1967)

Each primary viral-induced hamster tumor has its own characteristic morphology. The morphologic appearance varies in some tumors, frequently depending on their location andthe cell type affected. With other tumors the morphology changes on late-passage transplantation. Some of the viruses caused pathognomonic visceral lesions or characteristic giant cells. A few of the questions raised by the morphologic study of these lesions are briefly discussed in relation to pertinent virology and immunology. Morphologic studies in viral oncology may indeed shed more valuable information on many basic problems in this field.
Hyperthermia Enhancement of Antibody-Complement Cytotoxicity for Human Colon Tumor Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: W A Tompkins, G V Rama Rao, P Pantasatos, C A Cain
Journal: JNCI Journal of the National Cancer Institute (1981)

HCT-8R human colon tumor cells heated for 60 minutes at 37-44.5 degrees C showed an increased sensitivity to lysis by rabbit anti-HCT-8R antibodies and complement (Ab-C) at the higher temperatures. As compared to the 51Cr release assay, the colony formation (CF) assay was a more sensitive measure of hyperthermia-induced cell damage and sensitization to Ab-C lysis. Also the CF assay was more efficient than the 51Cr assay in detecting effects of low-temperature heating (41.5 degrees C) on Ab-C cytotoxicity. The direct toxicity of heating alone was minimal. Because heating did not influence the pH of the medium, the pH of our assay system did not appear to be factor in the enhanced sensitivity of heated cells to Ab-C cytotoxicity. Significantly smaller amounts of antibodies were capable of lysing heated cells as compared to unheated cells, but heated cells did not bind more antibodies than did unheated cells. This suggests that the hyperthermia effect on the cell occurs at some stage of the lytic event after antibody binding. Hyperthermia treatment at 43.5 degrees C enhanced cytotoxicity by antibodies monospecific to carcinoembryonic antigen, which is expressed on the surface of these cells. Thus hyperthermia may be an effective tool in augmenting specific immune reactions against tumor-associated cell membrane antigens.
Genome‐wide association study in mice identifies loci affecting liver‐related phenotypes including Sel1l influencing serum bile acids
Authors: Wei Wu, Ami Patel, Kaisa Kyöstilä, Hannes Lohi, Nikol Mladkova, Krzysztof Kiryluk, Xiaoyun Sun, Jay H. Lefkowitch, Howard J. Worman, Ali G. Gharavi
Journal: Hepatology (2016)

Using publicly available data from inbred mouse strains, we conducted a genome‐wide association study to identify loci that accounted for liver‐related phenotypes between C57BL/6J and A/J mice fed a Paigen diet. We confirmed genome‐wide significant associations for hepatic cholesterol (chromosome 10A2) and serum total bile acid concentration (chromosome 12E) and identified a new locus for liver inflammation (chromosome 7C). Analysis of consomic mice confirmed that chromosome 12 A/J alleles accounted for the variance in serum total bile acid concentrations and had pleiotropic effects on liver mass, serum cholesterol, and serum alanine aminotransferase activity. Using an affected‐only haplotype analysis among strains, we refined the chromosome 12E signal to a 1.95 Mb linkage disequilibrium block containing only one gene, sel‐1 suppressor of lin‐12‐like ( Sel1l ). RNA sequencing and immunoblotting demonstrated that the risk allele locally conferred reduced expression of SEL1L in liver and distantly down‐regulated pathways associated with hepatocyte nuclear factor 1 homeobox A ( Hnf1a ) and hepatocyte nuclear factor 4A ( Hnf4a ), known modifiers of bile acid transporters and metabolic traits. Consistent with these data, knockdown of SEL1L in HepG2 cells resulted in reduced HNF1A and HNF4A and increased bile acids in culture media; it further captured multiple molecular signatures observed in consomic mouse livers with reduced SEL1L. Finally, dogs harboring a SEL1L mutation and Sel1l +/− mice fed a Paigen diet had significantly increased serum total bile acid concentrations, providing independent confirmation linking SEL1L to bile acid metabolism. Conclusion : Genetic analyses of inbred mouse strains identified loci affecting different liver‐related traits and implicated Sel1l as a significant determinant of serum bile acid concentration. (H epatology 2016;63:1943‐1956)
The peculiarities of epidemiology of tuberculosis and respiratory diseases in Ukraine
Authors: Valentyna Matusevych, Vasyl Melnyk, Irina Novogilova
Journal: European Respiratory Journal (2014)

Aim-to appreciate the epidemiology of tuberculosis and respiratory diseases in Ukraine. Methods - analysis of reports for 2008-2012 years by statistical methods. The incidence (per 100000) of pulmonary TB in the newly detected patients had decreased from 77,8 in 2008 to 68,1 in 2012 (on 12,5 %), of TB mortality from 22,4 to 15,1 in 2012 (on 32,6 %) through the implementation ofthe TBprogram. The incidence of MDR TB was 15,3 per 100000 in 2012.One of the important problems in TB control there is a constant increase in the incidence and mortality from co-infection tuberculosis/HIV that had increased from 8,7 per 100000 in 2011 p. to 10,4 in 2012 (on 16,4 %).The favorable outcome of the treatment in NDP patients with MBT+ by cohort analysiswas 55,7 % (lower of WHO indicator - 85 %). Average length of stayof patients with TB was 100,8-112,8 days in hospital.The incidence of respiratory diseases remains highwith a tendency todecrease from 17379,5 to 16017,0 per 100000 of population (on 7,9 %),but the incidence of pneumonia (P) had increased from 394 to 414 per 100000 ( on 5 %), of chronic bronchitis had decreased from 255 to 192 per 100000. The incidence of bronchial asthma (BA) has stabilizedandwas 23,8 in 2008 and 23,5 in 2012. The mortality of all respiratory diseases had decreased from 50,4 to 37,4 per 100000, in particular of BA- from 0,7 to 0,4 per 100000, of P- from 14 to 11,8 per 100000, of chronic diseases of the lower respiratory tract from 30,5 to 21,1 per 100000. Conclusion: in Ukraine the epidemiological situation of TB has stabilized, the incidence of respiratory diseases remains highwith a tendency todecrease, the mortality of all respiratory diseases had decreased.
Decision protocol for airway stenting in relapsing polychondritis
Authors: Hiroshi Handa, Yoshihisa Yamano, Hiroki Nishine, Seiichi Nobuyama, Masamichi Mineshita, Teruomi Miyazawa
Journal: European Respiratory Journal (2014)

Background: Airway involvement in relapsing polychondritis (RP) is characterized by chondritis of the larynx and tracheobronchial tree. RP often causes tracheobronchomalacia (TBM), which can lead to dynamic airway collapse. TBM can be debilitating and life threatening, and pulmonary intervention is often required.

Objective: To establish a decision protocol for the placement of stents in RP patients with airway involvement.

Methods: This is a retrospective study of 44 RP patients treated at our department from January 2004 to November 2013. The McAdam or Damiani and Levine diagnostic criteria were used to diagnose RP in patients. Our decision protocol is as follows: first, medication therapy are administrated. If medication cannot stabilize the subglottic stenosis and/or TBM, tracheostomy and/or non-invasive positive pressure ventilation (NIPPV) should be performed to prevent dynamic airway collapse. Finally, if the airway cannot be maintained through medication and tracheostomy/NIPPV, stenting is required.

Results: Thirty-six of 44 RP patients developed airway involvements. Twenty-two RP patients were confirmed with TBM by chest CT and/or bronchoscopy.Six RP patients required tracheostomy. Ten RP patients required stenting with ultraflex stents and 1 underwent bifurcated silicone stent placement. TBM developed in the tracheobronchial tree of all RP patients, and 3 to 5 ultraflex stents were required to keep tracheobronchial patency. Ultraflex stents were successfully implanted at the flow-limiting segments (choke points).

Conclusion: Ultraflex stents were suitable for the central airway in RP patients with TBM. It is important to implant stents at the exact area of the flow-limiting segment.